Using Metformin to Treat Pulmonary Hypertension in Heart Failure Patients
Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
This study is looking at how the diabetes medication metformin might help older patients with heart failure and high blood pressure in the lungs, especially those with metabolic syndrome, to see if it can improve their heart and lung function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10460583 on NIH RePORTER |
What this research studies
This research investigates the effects of metformin, a common diabetes medication, on patients suffering from pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF). The study aims to better understand the specific characteristics of this patient group, particularly those who are older and may have metabolic syndrome. By examining how metformin influences pulmonary pressures and overall heart function, the research seeks to identify potential new treatment options for this challenging condition. Patients will be closely monitored for changes in their heart and lung function throughout the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with heart failure with preserved ejection fraction who also exhibit signs of pulmonary hypertension.
Not a fit: Patients without heart failure or those who do not have pulmonary hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option for patients with pulmonary hypertension and heart failure, potentially improving their quality of life and functional capacity.
How similar studies have performed: Previous studies have shown promising results with metformin in heart failure patients, suggesting that this approach may be a viable treatment option.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Simon, Marc a — University of California, San Francisco
- Study coordinator: Simon, Marc a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.